SCHEMBL15207711

SCHEMBL15207711

COc1ccc(Nc2nc3c(-c4ccc(C#N)nc4)nccn3n2)cc1OC

nearest known ligand 0.45

Predicted protein targets (top 19)

geneUniProtsupporting neighboursconfidence
PIK3CA P42336 1/20 0.45
SYK P43405 11/20 0.44
CD63 P08962 1/20 0.44
FLT3 P36888 3/20 0.43
CSNK2A1 P68400 1/20 0.42
TP53 P04637 1/20 0.42
GAA P10253 1/20 0.42
MAPT P10636 1/20 0.42
AURKA O14965 1/20 0.40
JAK2 O60674 1/20 0.40
KIT P10721 1/20 0.40
IRAK4 Q9NWZ3 1/20 0.40
PRKCQ Q04759 1/20 0.40
CDK4 P11802 1/20 0.39
CCND1 P24385 1/20 0.39
CCND2 P30279 1/20 0.39
CCND3 P30281 1/20 0.39
EIF2AK4 Q9P2K8 1/20 0.39
PLK1 P53350 1/20 0.39

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL31418 0.92 MAPT (0.41) PIK3CASYKCD63FLT3TP53
SCHEMBL15206787 0.89 JAK2 (0.48) GAAMAPTAURKAJAK2
SCHEMBL15207034 0.87 JAK2 (0.40) SYKJAK2EIF2AK4
SCHEMBL15207801 0.87 JAK2 (0.48) PIK3CASYKCD63FLT3TP53
SCHEMBL15206594 0.86 SYK (0.59) SYKCD63FLT3TP53GAA
SCHEMBL15207500 0.86 SYK (0.46) SYKCD63FLT3TP53GAA
SCHEMBL15207719 0.84 FLT3 (0.47) SYKCD63FLT3CSNK2A1TP53
SCHEMBL21097 0.84 SYK (0.44) SYKCD63FLT3TP53GAA
SCHEMBL21816 0.84 CHEK1 (0.49) SYKCD63FLT3TP53GAA
SCHEMBL19607 0.83 SYK (0.40) SYKGAAMAPTJAK2EIF2AK4

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 7 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-2609098-B1 TRIAZOLOPYRAZINE DERIVATIVES MERCK PATENT GMBH (DE) 2016-07-13 EP disclosed
US-9023851-B2 Triazolopyrazine derivatives MERCK PATENT GMBH (DE) 2015-05-05 US disclosed
US-9023851-B2 Triazolopyrazine derivatives MERCK PATENT GMBH (DE) 2015-05-05 US disclosed
US-9023851-B2 Triazolopyrazine derivatives MERCK PATENT GMBH (DE) 2015-05-05 US disclosed
US-20130225568-A1 TRIAZOLOPYRAZINE DERIVATIVES MERCK PATENT GESELLSCHAFT MIT BESCHRANKTER HAFTUNG (DE) 2013-08-29 US disclosed
US-20130225568-A1 TRIAZOLOPYRAZINE DERIVATIVES MERCK PATENT GESELLSCHAFT MIT BESCHRANKTER HAFTUNG (DE) 2013-08-29 US disclosed
US-20130225568-A1 TRIAZOLOPYRAZINE DERIVATIVES MERCK PATENT GESELLSCHAFT MIT BESCHRANKTER HAFTUNG (DE) 2013-08-29 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20130225568-A1 TRIAZOLOPYRAZINE DERIVATIVES SYK, IRAK1, ZAP70 PIK3CA 647/4885SYK 1/4885CD63 2804/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.